Hyperphosphatemia Management with Sevelamer and Lanthanum

Dosing and Administration

The American Journal of Kidney Diseases recommends starting lanthanum carbonate at 500-1000 mg three times daily with meals, then titrating every 2-3 weeks based on serum phosphorus response, with typical maintenance doses ranging from 1500-3000 mg daily 1
The American Journal of Kidney Diseases suggests taking lanthanum with or immediately after meals to maximize phosphate binding, and tablets should be chewed completely before swallowing for optimal absorption 1
The National Kidney Foundation guidelines, as reported in the American Journal of Kidney Diseases, recommend adjusting dose every 2-3 weeks based on serum phosphorus levels, targeting serum phosphorus of 3.5-5.5 mg/dL 1

The American Journal of Kidney Diseases notes that lanthanum requires significantly fewer tablets, with an average of 4 tablets daily, compared to 7 tablets daily for sevelamer, which may improve adherence in patients struggling with polypharmacy 2, 3

The American College of Physicians, as reported in the Annals of Internal Medicine, recommends restricting calcium-based binder doses when using sevelamer or lanthanum to avoid positive calcium balance, and excess calcium exposure increases vascular calcification risk across all CKD stages 4, 5
The American Journal of Kidney Diseases suggests considering sevelamer in patients with hypercalcemia or elevated calcium-phosphorus product, as it avoids calcium load, and may reduce mortality in incident dialysis patients based on trial data 1, 2, 3
The American Journal of Kidney Diseases recommends considering lanthanum when pill burden is a major adherence concern, as it requires fewer tablets, and may induce less adynamic bone disease than calcium carbonate 1, 2

The American Journal of Kidney Diseases recommends monitoring serum phosphorus every 2-4 weeks during titration, then monthly once stable, and intact PTH levels every 3 months 1, 2
The Annals of Internal Medicine suggests monitoring serum calcium for hypocalcemia, especially with concurrent calcimimetics, and restricting calcium-based binder doses to avoid positive calcium balance 4, 5
The American Journal of Kidney Diseases notes that phosphate binder therapy introduces major pill burden that seriously compromises adherence, and achieving normal phosphorus may not be possible or may unacceptably decrease quality of life 2, 6

The National Kidney Foundation's K/DOQI guidelines suggest that non-calcium-based binders like lanthanum are beneficial in preventing vascular calcification, with a relative phosphate-binding coefficient of 2.0, and may improve adherence through reduced pill burden, although they are more expensive than calcium-based options 7, 8, 9
Continuing calcium acetate poses significant cardiovascular risk, including progression of coronary and aortic calcification, while non-calcium binders like lanthanum prevent this progression, and also result in lower incidence of hypercalcemia and undesirable PTH suppression 7, 8, 9

The cost of non-calcium-based binders like lanthanum is justified by their clinical benefits in preventing vascular calcification and improving adherence through reduced pill burden, particularly in patients with swallowing difficulties 7, 8, 9

Renvela tablets should be swallowed whole and taken with meals; the optimal timing is 10–15 minutes before or during the meal to maximize phosphate‑binding efficacy in patients with chronic kidney disease. 10

Sevelamer must be separated from ciprofloxacin and other medications that interact with phosphate binders; dosing should be at least 1–2 hours before or 4 hours after sevelamer to avoid reduced absorption of the co‑administered drug. 11